top of page

Tindle on Medical Science

PAPERS IN PEER REVIEWED JOURNALS.

   6. Matutes E, Rodriquez B, Polli N, Tavares De Castro J, Parre IRA, A, Andrews C, Griffin JD, Tindle RW, Catovsky D. 

       (1985) Characterisation of myeloid leukaemias with monoclonal antibodies 3C5 and My9.  Haematological Oncology

       3:179-186.
 

   7. Michalevicz R, Katz F, Stroobant P, Janossy G, Tindle RW, Hoffbrand AV. (1985)  Platelet derived growth factor stimulates

       growth of highly enriched multipotent haemopoietic progenitors. British.Journal  of  Haematology Brit.J.Haematol. 63:591-8.
 

   8. Slater, HR, Tindle RW, Packard CJ, Shepherd J (1985).  A monoclonal antibody based immunoradiometric assay for

       Apoprotein B in low-density lipoprotein.  Clinical Chemistry 31/6:841-845.
 

   9. Martin H, Hibbin JA, Dowding C, Matutes E, Tindle RW, Goldman JM. (1986)  Purification of haemopoietic progenitor cells

      from patients with chronic granulocytic leukaemia using percoll density gradients and delutriation. British.Journal 

      of Haematology. 63/1 187-99

10. Watt SM, Katz FE, Davis L, Capellaro D, Gordon MV, Tindle RW, Greaves MF.(1987) Expression of HPCA-1                                          and  HLA-DR antigens on growth factor and stroma dependent colony forming cells.  British.Journal of Haematology.                      66/2:153-9.
 

11. Batinic D, Tindle RW, Boban D, Tiefenbach A, Rajic L, Labar B, Nemet D, Boranic M. (1988).  Expression of haematopoietic             progenitor cell-associated antigen B1-3C5/CD34 in leukaemia.  Leukaemia Research 13/1: 83-85
 

12. Tindle RW, Park D, Frazer IH.  (1990).  The immunology of human papillomavirus infection of the anogenital epithelium.              J.Gynecol Surg. 6, 11-19.

 

13. Tindle RW.  (1990).  Genital warts:  Molecular Biology and Immunology.  Immunol. Cell.Biol.68, 71-74

 

14. Tindle RW, Smith J, Geysen M, Selvey L, Frazer I. (1990)  Identification of B-
      epitopes in human papillomavirus (HPV)16 E7 open reading frame (orf) protein. Journal of  General Virology71:1347-1354.
 

15. Selvey L, Tindle RW, Geysen M, Frazer I. (1990).  Monoclonal antibodies define the B-epitopes of human papillomavirus                  (HPV) 18 E7 transforming peptide.  Journal of Immunology. 145/9. 3105-10.
 

16. Tindle RW,  Frazer IH, (1990).  Immunology of Anogenital Human Papillomavirus (HPV) Infection.  Aust. N.Z. J. Obstet.                  Gynaecol.  30 4. 370-375.
 

17. Tindle RW, Zhou WD, Saul A, Frazer IH. (1990).  The molecular specificity of linear B-epitopes in the E7 open reading frame           (E-ORF) protein of human papillomavirus (HPV) 16 defined by monoclonal antibodies.  Peptide Research 3/4.  162-166.
 

18. Smillie AE, Tindle RW, O'Connor DT, Kennedy L, Frazer IH(1991). Humoral response to human papillomavirus genotype 16          and 18 open reading antigens in subjects with ano-genital papillomavirus infection and controls. Immunology and Infectious          Diseases. 1, 13-17.

 

19. Tindle RW, Fernando GJP, Sterling JL, Frazer IH (1991).  A 'public' T-helper epitope of the E7 transforming protein of human          papillomavirus 16 provides cognate help for several E7 B-epitopes from cervical cancer associated HPV genotypes.                            Proc.Nat.Acad.Sci.(USA) 88, 5887-5891.

 

20. Frazer IH, Tindle RW (1992).  Cell mediated immunity in human papillomavirus infection. Papillomavirus Report, 3/3:53-58.

 

21. Selvey LA, Dunn L, Tindle RW, Frazer IH (1992).  An Elisa capture assay for the E7 transforming proteins of HPV 16 and 18.              Journal of Virological.Methods 37, 119-128.

 

22. Tindle RW, Herd K, O'Connor D, Kennedy L, Frazer IH (1992).  Reactivity of serum antibodies from patients with human                papillomavirus 16 (HPV 16) associated anogenital lesions with peptides of the E7 transforming protein. Immunology and                  Infectious Disease 2,223-238.
 

23. Stacey SN, Ghosh A, Bartholomew JS, Tindle RW, Stern PL, Mackett M, Arrand JR(1993).  Expression of human                                  papillomavirus type 16 E7 protein by recombinant baculovirus and use for the detecion of E7 antibodies in sera from cervical          carcinoma patients. J.Med.Virol.40:14-21.

 

24. Smeland EB, Funderud S, Kralheim G, Gaudernack G, Rasmussen AH, Rusten L, Mu W, Tindle RW, Blomhoff HK, Egeland T          (1992). Effective isolation of human progenitor cells; a new method for detachment of immunomagnetic beads from                          positively selected CD34+cells. Leukemia 6/8, 845-852.

 

25. Tindle RW, Frazer IH(1994). Immune responses to Human Papillomavirus and the prospects for HPV specific immunisation.          Current Topics in Microbiology and Immunology 186:217-252.

 

26. Tindle RW, Herd K, Londono P, Fernando GJP, Chatfield SN, Malcolm K, Dougan G (1994).  Chimeric hepatitis B core antigen        particles containing B- and Th-epitopes of human papillomavirus type 16 E7 protein induce specific antibody and T-helper            responses in immunised mice.  Virology 200:547-557.
 

27. Fernando GJP, Tindle RW, Frazer HI, Stenzel DJ, Merza MS, Mortein B(1994).  Small synthetic peptides as vaccines:  A model          peptide/ISCOM construct from cancer-associated human papillomavirus.Vaccines 94, Cold Spring Harbor Laboratory Press,          327-331.

 

28. Selvey LA, Dunn LA, Tindle RW, Park DS, Frazer IH. HPV18 E7 protein is a short-lived steroid inducible phosphoprotein in            HPV transformed cell lines.  Journal of General Virology 75:1647-1653.

 

29. Kadish AS, Romney SL, Ledwidge R, Tindle RW, Fernando GJP, Zee SY, Van Ranst MA, Burk RD(1994).  Cell-mediated                      immune response to HPV17 E7 peptides are dependent on HPV type infecting the cervix:  Discordance between cell mediated        and ELISA reactivity. Journal of General.Virology 75:2277-2284.

 

30. Fernando GJP, Stenzel DJ, Tindle RW, Merza MS, Morein B, Frazer IH(1995). Peptide polymerisation facilitates incorporation         into ISCOMS and increases antigen specific IgG2a production Vaccine 13/15 1460-2284

 

31. Fernando GJP, Tindle RW, Frazer IH(1995). T-helper epitopes of the E7 transforming protein of cervical cancer associated                human papillomavirus type 18 (HPV 18) Virus Research 36(1):1-13.
 

32. Tindle RW, Croft S, Herd K, Malcolm K, Geczy AF, Steward T, Fernando GJP(1995).  A vaccine conjugate of 'Iscar'                                 immunocarrier and peptide epitopes of the E7 cervical cancer associated protein of Human Papillomavirus type 16 elicits                 specific Th1 and Th2 type responses in immunised mice in the absence of oil based adjuvants.                                                                 Clinical.Experimental.Immunology.102/2:265-271.

 

33. Frazer IH, Lieppe D, Dunn L, Griepe L, Tindle RW, Fernando G, Phelp W, Lambert P(1995).  An HPV16 E6/E7 transgenic                  mouse mimics the immunobiology of HPV associated cervical cancer. Cancer Research 55:2635-2639.
 

34. Tindle RW, Frazer IH(1995). Human papillomavirus infection, genital warts and cervical cancer: prospects for prophylactic               and therapeutic vaccines.  Exp.Opin.Invest.Drugs 4/9:783-797.
 

35. Londono P, Chatfield S, Tindle RW, Gao XZ, Frazer IH, Dougan G(1996).  Immunisation of  mice using Salmonella                            typhimurium expressing Human Papillomavirus Type 16 E7 epitopes inserted into Hepatitis B virus core antigen. Vaccine 14/6        545-52.

 

36.  Tindle RW (1996). Vaccines for Cervical Cancer. Current Opinion in Immunology 8:643-50.

 

37. Zerfass-Thome K, Zwerschke W, Mannhardt B, Tindle RW, Botz JW, Jansen-Durr P(1996).  Inactivation of the cdk inhibitor              p27KIP1 by the human papillomavirus type 16 E7 oncoprotein.  Oncogene 13(11):2323-2330.

 

38. Herd K, Fernando GJP, Dunn LA, Frazer IH, Lambert P, Tindle RW (1997). E7 oncoprotein of Human Papillomavirus type 16          (HPV 16) expressed constitutively in the epidermis has no effect on E7-specific B- or Th-repertoires or on the immune                       response induced or sustained after immunisation with E7 protein. Virology 231:155-165.

 

39. Tindle RW(1997).  Human Papillomavirus: an Immunological perspective in 'Papillomavirus Reports' 8/1:3-4
 

40. Dunn LA, Evander M, Tindle RW et al. (1997).  Presentation of HPV16 E7 skin grafts is insufficient to allow graft rejection in an         E7 primed animal.  Virology  235 94-103

 

41. Tindle RW. Immunomanipulative strategies for the control of human papillomavirus associated disease  1997.  Immunologic          Research 16/4:313-326.43.

 

42. Fernando, GJP., Stewart, TJ., Tindle, RW, Frazer, IH.(1998)  Vaccine induced Th1 responses are dominant in the short term,              whereas pre-existing Th2 responses are dominated in the longer term. Scandinavian Journal of Immunology  47,459-465

 

43. Doan,T, Chambers, M., Street, M., Fernando, G., Herd, K., Lambert P., Tindle,RW. (1998) Mice expressing the E7 oncogene of          HPV16 E7 in epithelium show evidence of peripheral anergising tolerance to E7 encoded CTL epitopes. Virology 244: 352-364.              
 

44. Fernando, GJP, Stewart, TJ, Tindle RW, Frazer IH. (1998)  Th2 type CD4+ cells neither enhance nor suppress anti-tumour CTL        activity in a mouse tumor model.  Journal of .Immunology. 161 2421-2427.
 

45. Frazer IH., Fernando, GJP., Fowler, N, Leggat,G.,Lambert,P., Liem,A., Malcolm K, Tindle RW (1998) Split tolerance to a viral            antigen expressed in thymic epithelium and keratinocytes. European Journal of Immunology . 28 2791-2800

 

46. Doan T, Herd, K, Street ,M. Bryson, G., Fernando,G., Lambert,P., and Tindle,RW. (1999). Human papillomavirus type 16 E7              oncoprotein expressed in peripheral epithelium tolerises E7-directed CTL precursors restricted through human (and mouse)          MHC class 1 alleles. Journal of Virology 73/7 6166-6170

 

47. Street,M., Herd,K., Londono,P., Dougan, G., Kast,M., and Tindle, RW (1999). Differences in the effectiveness of delivery of B-            and CTL- epitopes incorporated  into the Hepatitis B core antigen (HBcAg) c/e1 region. Archives of Virology 144:1-21

 

48. Street, M., and Tindle,RW. (1999). Vaccines for human papillomavirus associated anogenital disease and cervical cancer;                    practical and theoretical approaches. J. Invest. Drugs. 8(6): 761-776.

 

49. Frazer, IH., Thomas,R., Zhou,J., Leggatt,G., Dunn, L., McMillan N., Tindle,RW,  Filgueira L., Barnard, P., Sharkey, M. (1999).            Potential Strategies    used by papillomavirus to evade host cell immunity. Immunological Reviews.168 131-42

 

50. Peng S, Qi YM, Christensen N, Hengst K, Kennedy L, Frazer IH, Tindle RW. (1999) Capture ELISA and in vitro cell-binding               assay for the detection of antibodies to human papillomavirus type 6B virus-like particles in patients with anogenital warts .             Pathology 31 418-422

 

51. Azoury-Ziadeh R, Herd K, Fernando, GJP, Frazer IH and Tindle RW. (1999). T-helper epitopes identified within the the E6               transforming protein if cervical cancer associated human papillomavirus type 16 (HPV 16). Viral Immunology  12/4 292-312

 

52. Tindle, R.W. (2001) Peripheral tolerance as defined through transgenic animal  studies.  Autoimmunity 33, 135-149.

 

53. Doan, T, Herd, K., Lambert, P., Fernando, GJP., Street, M, and Tindle RW (2000) Peripheral tolerance to Human                                Papillomavirus Oncoprotein occurs by cross-tolerisation , is largely Th2 independent, and is broken by dendritic cell                        immunisation. Cancer Research 60, 2810-2815.

 

54. Azoury-Ziadeh, R., Herd, K., Fernando, GJP., Lambert, P., Frazer,IH., and Tindle, RW (2001) . Low level expression of human          papillomavirus type 16 (HPV16) E6 in squamous epithelium does not elicit E6 specific B- or T-helper immunological                        responses, or influence the outcome or immunisation with E6 protein. Virus Research  73 189-199.

 

55. Netter, HJ., MacNaughton, TB., Woo,W-P., Tindle,R. and Gowans EJ (2001) Antigenicity and immunogenicity of novel                        chimeric hepatitis B surface antigen particles with exposed HCV-epitopes.  Journal of Virology  75,2130-2141

 

56. Tindle, RW., Herd, K., Doan, T. Bryson, G., Leggatt, G., et. al. (2001) Non-specific down-regulation  of CD8+ive T-cell                         responses in mice expressing Human Papillomavirus type 16 E7 oncoprotein from the keratin-14 (K14) promoter. Journal of            Virology 75/13

 

57. Tindle, RW. (2002) Immune evasion in human papillomavirus - associated cervical cancer. Nature Reviews Cancer 2 59-66 .

 

58. Street, MD., Doan,T., Herd, K., and Tindle, RW. (2002) Limitations of HLA-transgenic mice in presentation of HLA-restricted        human papillomavirus type 16 cytotoxic T cell epitopes from endogenously processed antigen.  Immunology 1006, 526-536

 

59. Khammanivong, V., Liu, X.S., liu, W.J., Rodda, S.J., Leggett, G.R., Tindle, R.W, Frazer, I.H., Fernando, G J.P. (2003). Paucity of            functional CTL epitopes in the E7 oncoprotein of cervical cancer associated human papillomavirus type 16. Immunology and          Cell Biology 81, 1-7

 

60. Netter, HJ., Woo,WP., Tindle,RW.,   Roderick I. MacFarlan, Gowans,EJ. (2003) Immunogenicity of recombinant HBsAg/HCV           particles in mice pre-immunised with hepatitis B virus specific vaccine .  Vaccine  3811,1-6

 

61. Wiethe, C., Dittmar, K., Doan, T., Lindenmaier, W., and Tindle RW. (2003) Provision of 4-1BBL enhances effector and memory        CTL responses generated by immunisation with dendritic cells expressing a human tumour associated antigen. Journal of                 Immunology 170, 2912-2922

 

62. Ward, SM., Tindle, RW., Khromykh,A., Gowans, EJ.  (2003) Generation of CTL responses using Kunjin replicon RNA.                         Immunology and Cell Biology 81,73-78

 

63. Weithe C.,  Dittmar, K., Doan, T., Lindenmaier,W., and Tindle, RW. (2003) Enhanced  effector and memory CTL responses              generated by incorporation of RANK/RANKL costimulatory molecules into dendritic cell immunogens expressing a tumour          specific antigen. Journal of Immunology 171, 4121-4130.

 

 

64. Herd, K., Harvey, T., Khromykh, AA and Tindle RW. (2004). Protective  T cell immunity against a human papillomavirus 16            E7-expressing tumour induced by recombinant Kunjin virus replicon vaccines. Virology 319, 237-248.

 

65. Doan, T., Herd, K., Ramshaw, I., Thomson, S., and Tindle, RW. (2005) A polytope DNA vaccine elicits multiple effector and              memory CTL responses and protects against human papillomavirus 16 E7-expressing tumour. Cancer Immunology and                  Immunotherapy .54 57-171

​

66. Herd, KA., Mahalingam,S., Mackay, IM., Nissen, M., Sloots P., and Tindle, RW (2006). Cytotoxic T lymphocyte (CTL) epitope           vaccination against human metapneumovirus (hMPV) infection and disease in mice. Journal of Virology .80/4 2034-44

 

67. Woo, Y., Doan, T., Herd, KA, Netter, H., and Tindle, RW (2006). Hepatitis B surface antigen (HBsAg) vectors delivers protective        CTL responses to disease-relevant foreign epitopes.  Journal of Virology  80/8 3975-3984

 

68. Herd, KA., Wiethe, C., and Tindle RW (2007). Co-immunisation with DNA encoding RANK/RANKL or 4-1BBL costimulatory          molecules does not enhance effector or memory CTL responses afforded by tumour-antigen encoding DNA vaccines. Vaccine        25 5209-5216

 

69. Haigh, O., Guo, H., Edgtton, K., Mather, M., Herd, KA, and Tindle RW (2007) Multiplecopies of a tumor epitope in a                          recombinant hepatitis B surface antigen (HBsAg) vaccine enhance CTL responses, but not tumor protection. 368 363-75

 

70. Thomson, S., Haigh, O., Gould, A., Tindle, RW (2008)  Genetically modified Hepatitis B surface antigen: a powerful vaccine             technology for the delivery of disease-associated foreign antigens (Invited Review). Current Drug Therapy 3/3 226-234

 

71. Herd KA.,   Nissen  MD.,, Hopkins, PM.,, Sloots,TP., and Tindle,RW (2008).MHC  class-I cytotoxic T-cell immunity to human           metapneumovirus (hMPV) in individuals with previous hMPV infection and respiratory disease. Journal of Infectious Diseases       197/4 581-582

 

 

72. Tindle, RW., Haigh, O., Gould,A., Thomson, S. (2008)  Recombinant Hepatitis B surface antigen vaccines for the delivery of           disease-related antigens (Invited Review) Current Trends in Immunology 9, 52-60.

 

73. Gu W, Cochrane M, Leggatt GR, Payne E, Choyce A, Zhou F, Tindle R, McMillan NA (2009). Both treated and  untreated                  tumors are eliminated by short hairpin RNA-based induction of target-specific immune responses..Proc Natl Acad Sci U S A.            106(20):8314-9

 

74. Dekun Chen,  Kristy Edgtton, Allan Gould, Huayang Guo, Michael Mather,  Oscar Haigh, Melanie Cochrane, Jacqueline                    Kattenbelt, Scott Thomson, Robert Tindle (2010). HBsAg-vectored vaccines simultaneously deliver  CTL responses to                      protective epitopes from multiple viral pathogens. Virology 1/398 68-78

​

75. Oscar Haigh, Jacqueline Kattenbelt,  Melanie Cochrane, Scott Thomson  Allan Gould, Robert Tindle (2010). Hepatitis B                    surface antigen fusions delivered by DNA vaccination elicit CTL responses to human papillomavirus oncoproteins                           associated with tumor protection. Cancer Gene Therapy 17/10 708-20.

​

76. Karen A. Herd, Michelle Nelson, Suresh Mahalingam, and  Robert W. Tindle  (2010)Pulmonary infection of mice with human        metapneumovirus induces local cytotoxic T cell and immunoregulatory cytokine responses similar to those seen with human        respiratory syncytial virus. Journal of General Virology 91 1302-1310

Book Chapters

1. Birnie GD, Wiedemann LM, Burns TH, Warnock AM, Tindle RW.  A possible approach to the classification of human                        leukaemia by molecular hybridisation.  Frontiers in Experimental Haematology.  Ed. U. Torelli, GP. Bagnara, MA, Brunelli C,          Vastaldine AU, DiPrisco, Serono Symposium, Roma, 1983.

​

2. Tindle RW, Catovsky D, Nichols RAB, Campana D, Chan LC.  1985. Monoclonal antibody BI-3C5 reacts specifically with MI/M2      acute myeloid leukaemias and most non-B non-T acute lymphocytic leukaemias, and recognises a small population of                      immature cells in normal bone marrow.  In “Protides of the Biological Fluids.”  897-900   Ed.H. Peeters, pub. Pergammon Press      1985.
 

3. Tindle RW, Catovsky D,   Matutes E, Nichols RAB, Chan L, Campana D, Birnie GD.  1985.  Monclonal antibody BI-3C5 of use in      the classification of acute leukaemias in “The Cytobiology of Leukaemias and Lymphomas” Eds. D. Quaglina, FGJ Hayhoe                Serono Symposium.  Vol 20. Pub. Raven Press (New York) 1985.

​

4. Tindle RW, Frazer IH(1997). Vaccines for Papillomaviruses. In New Generation    Vaccines, Ed. M.Levine, Pub.        M.Dekker,          New York. 50:1-15.
 

5. Tindle, R.W.  Immunomodulation of HPV infection and disease in ‘Vaccines for Human Papillomavirus   Infection and Disease’.      Ed. Tindle RW, Published Landes Bioscience Austin, USA 1999.

 

6. Frazer, IH., Tindle, RW., Fernanado, G.J.P., Malcolm, K., Herd, K. McFadyn, S., Cooper, P.D. and Ward, B.  Safety and                           immunogenicity of HPV16 E7/Algammulin immunotherapy for cervical in ‘Vaccines for Human Papillomavirus Infection and         Disease’. Ed. Tindle RW, pubs Landes Bioscience (Austin, USA) 1999

Other Publications 

  1. Tindle RW, Neoh, SH, Ashley MP, Hardy D, Kotlarski I (1976) Resistance of mice to Krebs Ascites tumour, Sarcoma S180 and PC6 Plasmacytoma after immunisation with Salmonella Enteriditis IIRX.  Aust.J.Biol.Med.Sci. 54/2:149-155.
     

  2. Birnie G, Weidemann L, Burns J, Warnock M, Tindle RW, Graham S et al (1983).  A new approach to the classification of human leukaemias:  Measurement of the relative abundance of a specific RNA sequence by molecular hybridisation.  Lancet Vol. 1:197-200.
     

  3. Tindle RW, Nichols RAM, Li Chan, Campana D, Catovsky D, Birnie GD (1985).  A novel monoclonal antibody BI-3C5 recognises myeloblasts and non-B, non-T lymphoblasts in acute leukaemias and CGL blast crises, and reacts with immature cells in normal bone marrow.  Leukaemia Research 9/1:1-9.
     

  4. Katz RE, Tindle RW, Sutherland DR, Greaves M (1985).  Identification of a membrane glycoprotein associated with haemopoietic progenitor cells.  Leukaemia Research 9/2:191-198.
     

   5. Graham SV, Tindle RW, Birnie G.(1985).  Variation in myc gene amplification and expression in sub-lines of

       HL60cells. Leukaemia Research 9/2: 239-249.

1. Rodriquez B, Polli N, Tavares De Castro JM, Matutes E, Tindle RW, Griffin D, Catovsky D.  1984   Studies with the monoclonal          antibodies BI-3C5 and MY906 in normal and leukaemic cells Brit. J. Haematol. J8:186-187.

​

2. Katz FE, Tindle RW, Sutherland R, Greaves MF.  1985.  Reactivity of a monoclonal antibody defining human haematopoietic          multipotential progenitors in Proceedings of the Second International Meeting on Leucocyte Differentiation Antigens, Boston        1985.
 

3. Katz FE, Watt SM, Lam G, Capellaro D, Tindle RW, Greaves MF.  1987.  Co-ordinate expression of BI-3C5 (CD34) and HLA-DR        antigens on normal and malignant hemopoetic precursor cells.  In “Proceedings of the 3rd International Workshop on                      Leucocyte Differentiation Antigens”.  Oxford University Press, Oxford 655.
 

4. Tindle RW, Catovsky D, Griffin J, Janossy G, Chan L.  1985.  A novel anti-   myeloid antibody recognises early myeloid and                 some lymphoid precursors and sub-classifies human acute leukaemias in “Monoclonal Antibodies in Haematopathology”  Pub.      Chruchill.  1985

 

5. Frazer IH, Whiteman DC, Tindle RW, Kennedy L, O’Connor D, 1988.  HPV detection in small clinical biopsies:  Comparison of      a commercial DNA probe based kit with a DNA probe based dot blot assay.  Venereology 1/1.36.
 

6. Tindle RW, Smith J, Geysen M, Selvey L, Frazer I (1989).  Human papillomavirus (HPV): Monoclonal antibodies to the E7                 transforming protein.  J.Cellular Biochemistry 13c 234.
 

7. Tindle RW, Uchanska-Ziegler B. (1989)  Summary of CD 34 Cluster Workshop Section:  In ‘Leucocyte Typing IV” Proceedings        of the IVth International Leucocyte Antigens Conferences, Vienna 1988.  Ed W Knapp, Oxford University Press.
 

8. Frazer IH, Dunn LA, Fernando GJP, Tindle RW, Lieppe DM, Lambert PF. (1995). HPV transgenic skin is not rejected in E7                immunised mice.  J.Cellular Biochemistry 19A 310.

 

 

9. Frazer IH, Tindle RW (1996). Cell-mediated immune responses in Human   Papillomavirus infection. In 'Current Research on        Papillomavirus' Ed.C. Lacey. Pub.Leed Univ. 151-163

bottom of page